UNIVERSITY OF UTAH
TAMPA, Utah
Total Received
$491.2M
Total Awards
240
State
Utah
Last Updated
Mar 20, 2026
Yearly Funding Trend
$406.2M24
$79.8M25
$5.2M26
Top 50 Awards to UNIVERSITY OF UTAH
Largest individual federal awards on record for this recipient, ranked by obligated amount. Data through March 20, 2026.
| Award | Awarding Agency | Program | Place | FY | Obligation |
|---|---|---|---|---|---|
ASST_NON_P30CA076292_075 MOFFITT CANCER CENTER SUPPORT GRANT - UNDER LEADERSHIP OF ITS FOURTH CENTER DIRECTOR, JOHN L. CLEVELAND, PHD, THE SINGULAR MISSION OF MOFFITT CANCER CENTER (“MOFFITT”), ESTABLISHE… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | FL-90 | 2024 | $67,429,131 |
ASST_NON_U54CA163068_075 2/2 PONCE HEALTH SCIENCES UNIVERSITY-MOFFITT CANCER CENTER PARTNERSHIP - THE COMMUNITIES IN THE PONCE AND TAMPA BAY REGIONS EXPERIENCE BOTH SHARED AND UNIQUE CHALLENGES ASSOCIATED… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | FL-90 | 2024 | $20,571,141 |
ASST_NON_HT94252520006_097 USING COMBINATORIAL THERAPIES WITH DENDRITIC CELL THERAPIES TO IMPROVE SURVIVAL AND PREVENT RECURRENCE OF BREAST CANCER LEPTOMENINGEAL DISEASE (LMD) | Department of Defense Defense Health Agency | 12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT | TAMPA, FL-14 | 2025 | $18,696,738 |
CONT_AWD_HHSN26800003_7529_HHSN268201400003I_7529 THE NATIONAL MYELODYSPLASTIC SYNDROMES (MDS) NATURAL HISTORY STUDY, CENTRAL LAB AND BIOREPOSITORY (CLB), TASK ORDER 03 | Department of Health and Human Services National Institutes of Health | — | TAMPA, FL-15 | 2024 | $12,953,436 |
ASST_NON_W81XWH1610385_097 CORRECTING THE ANTI-HER-2 CD4 TH1 RESPONSE IN BREAST CANCER THERAPY TO PREVENT RECURRENCE THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE $13,151.29, AS A RESULT OF THE COMPLETI… | Department of Defense Defense Health Agency | 12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT | TAMPA, FL-15 | 2024 | $10,850,836 |
ASST_NON_P01CA250984_075 IDENTIFYING METABOLIC VULNERABILITIES IN LUNG CANCER - OVERALL PROJECT SUMMARY IDENTIFYING METABOLIC VULNERABILITIES IN LUNG CANCER LUNG CANCER IS THE MOST COMMON CAUSE OF CANCER… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | TAMPA, FL-15 | 2024 | $10,093,168 |
ASST_NON_W81XWH1910675_097 NOVEL IMMUNOTHERAPY FOR BRAIN-METASTATIC BREAST CANCER | Department of Defense Defense Health Agency | 12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT | TAMPA, FL-15 | 2024 | $8,318,389 |
ASST_NON_U01CA200464_075 QUANTITATIVE IMAGING CLINICAL VALIDATION CENTER AT MOFFITT CANCER CENTER - PROJECT SUMMARY/ABSTRACT AN OVERARCHING GOAL OF CANCER SCREENING IS TO DETECT CANCER AT AN EARLY STAGE W… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | TAMPA, FL-15 | 2024 | $7,906,350 |
ASST_NON_R35CA197452_075 IDENTIFICATION OF NON-CODING RNAS TO THERAPEUTICALLY TARGET UNDRUGGABLE PATHWAYS IN METASTATIC LUNG ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA - DESCRIPTION (PROVIDED BY APPL… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | TAMPA, FL-15 | 2024 | $6,358,002 |
ASST_NON_U54CA274507_075 THE DELTA ECOLOGY OF NSCLC TREATMENT - SUMMARY – MOFFITT CSBC PROPOSAL OVERVIEW THE MOFFITT CSBC PROPOSAL IS FOCUSED ON THE ESSENTIAL AND HIGHLY DYNAMICAL INTERPLAY BETWEEN CANCE… | Department of Health and Human Services National Institutes of Health | 93.397 CANCER CENTERS SUPPORT GRANTS | FL-90 | 2024 | $6,315,009 |
ASST_NON_R01AI067846_075 ROLE OF BCL11B IN CD4+ T CELLS AND INNATE LYMPHOID CELLS - SUMMARY TYPE TWO IMMUNE DISEASES SUCH AS ASTHMA, ALLERGIES AND CHRONIC RHINOSINUSITIS REMAIN IMPORTANT HEALTH AND ECONOM… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | FL-90 | 2025 | $5,761,364 |
ASST_NON_R01CA141244_075 ALLOSTERIC REGULATION OF MDMX BY PROTEIN DISORDER - MDMX AND MDM2 ARE HOMOLOGUES THAT REGULATE THE P53 TUMOR SUPPRESSOR USING DIFFERENT MECHANISMS. WHILE MDM2 IS RESPONSIBLE FOR C… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | FL-90 | 2024 | $5,229,912 |
ASST_NON_R37CA229810_075 USING RADIOGENOMICS TO NONINVASIVELY PREDICT THE MALIGNANT POTENTIAL OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS OF THE PANCREAS AND UNCOVER HIDDEN BIOLOGY - PROJECT SUMMARY/ABSTR… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | FL-90 | 2024 | $4,961,820 |
ASST_NON_U24CA231877_075 A FEDERATED GALAXY FOR USER-FRIENDLY LARGE-SCALE CANCER GENOMICS RESEARCH - PROJECT SUMMARY CANCER RESEARCH IS NOW A DATA-DRIVEN DISCIPLINE, BUT ONLY A MINORITY OF CANCER RESEARCH… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | OR-90 | 2025 | $3,849,867 |
ASST_NON_R01CA268973_075 HIV GENOMIC AGING PROJECT IN ONCOLOGY (HIV-GAP) - ABSTRACT. PEOPLE WITH HIV (PWH) EXPERIENCE HIGHER CANCER MORTALITY AND INCREASED LIKELIHOOD OF CANCER RELAPSE AFTER INITIAL THERA… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | TAMPA, FL-15 | 2024 | $3,820,924 |
ASST_NON_U01CA274971_075 ADVANCING CLINICAL TRIALS: WORKING THROUGH OUTREACH, NAVIGATION AND DIGITAL ENABLED REFERRAL AND RECRUITMENT STRATEGIES (ACT WONDERS) - ABSTRACT LIMITED PARTICIPATION OF RACIAL/ET… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | FL-90 | 2024 | $3,673,561 |
ASST_NON_R01CA249689_075 CARES-REACH (COLORECTAL CANCER AWARENESS, RESEARCH, EDUCATION AND SCREENING-RURAL EXPANSION, ACCESS AND CAPACITY FOR HEALTH) - ABSTRACT DESPITE THE HEALTHY PEOPLE 2020 GOAL OF 70.… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | FL-90 | 2024 | $3,663,072 |
ASST_NON_R01CA227073_075 DEVELOPMENT OF NEW CASEIN KINASE 1 INHIBITOR FOR THE TREATMENT OF BRAIN CANCERS - HIGH GRADE GLIOMAS, ESPECIALLY GLIOBLASTOMA (GBM), HAVE EXCEPTIONALLY POOR PROGNOSIS AND CANCERS… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | FL-90 | 2025 | $3,594,455 |
ASST_NON_R01CA214588_075 INVESTIGATION OF ORAL HPV INFECTION NATURAL HISTORY AND BIOMARKERS OF PERSISTENT INFECTION: THE HIM STUDY - ABSTRACT IN 2013, 42,440 ADULTS IN THE U.S. WERE DIAGNOSED WITH OROPHA… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | TAMPA, FL-15 | 2024 | $3,566,476 |
ASST_NON_R01CA262530_075 DEVELOPING CDK12 INHIBITORS TO OVERCOME THERAPY RESISTANCE IN HER2+ AND KRAS DRIVEN BREAST AND LUNG CANCERS - PROJECT SUMMARY ALTHOUGH THE DEVELOPMENT OF TARGETED THERAPIES HAS IM… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | TAMPA, FL-15 | 2024 | $3,519,313 |
ASST_NON_R01CA223823_075 THERAPEUTIC TARGETING OF CASEIN KINASE-1-DELTA IN PRIMARY AND METASTATIC BREAST CANCER - OUR MULTI-PI RESEARCH TEAM RECENTLY REPORTED THAT THE DELTA ISOFORM OF CASEIN KINASE-1 (CK… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | TAMPA, FL-15 | 2024 | $3,509,398 |
ASST_NON_R37CA222215_075 COMBINED RADIATION ACOUSTICS AND ULTRASOUND IMAGING FOR REAL-TIME GUIDANCE IN RADIOTHERAPY - PROJECT SUMMARY: RADIOTHERAPY CAN BE A HIGHLY EFFECTIVE TREATMENT FOR MANY TYPES OF CA… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | FL-90 | 2024 | $3,462,931 |
ASST_NON_R01CA219389_075 IMPROVING PREDICTION OF CHEMOTHERAPY-INDUCED NAUSEA: INTEGRATING GENES, BEHAVIOR, AND THE MICROBIOME - PROJECT SUMMARY MODERATE TO SEVERE NAUSEA IS REPORTED BY UP TO 38% OF CANCER… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | FL-90 | 2024 | $3,461,907 |
ASST_NON_U54CA277834_075 PARTNERSHIP TO ASSESS VIRAL AND IMMUNE LANDSCAPE INTERSECTIONS WITH ONCOLOGY FOR PEOPLE LIVING WITH HIV (PAVILION) - PROJECT SUMMARY – OVERALL THE PARTNERSHIP CENTER, ENTITLED PAR… | Department of Health and Human Services National Institutes of Health | 93.989 INTERNATIONAL RESEARCH AND RESEARCH TRAINING | TAMPA, FL-15 | 2024 | $3,426,827 |
ASST_NON_R37CA234021_075 DEVELOPING AND CREDENTIALING PATIENT-DERIVED XENOGRAFT MODELS TO ADVANCE THERAPEUTIC APPROACHES FOR CHRONIC MYELOMONOCYTIC LEUKEMIA - PROJECT SUMMARY/ABSTRACT CHRONIC MYELOMONOCYT… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | FL-90 | 2024 | $3,422,767 |
ASST_NON_R01CA249016_075 RADIOMICS AND PATHOMICS TO PREDICT UPSTAGING OF DCIS - ABSTRACT DUCTAL CARCINOMAS IN SITU (DCIS) OF THE BREAST ARE A HETEROGENEOUS GROUP OF NEOPLASTIC LESIONS THAT ARE USUALLY DE… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | TAMPA, FL-15 | 2024 | $3,369,053 |
ASST_NON_R01CA239219_075 IMAGING ACIDOSIS AND IMMUNE THERAPY IN PDAC - ABSTRACT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IS THE MOST LETHAL OF ALL CANCERS AND IS LARGELY RESISTANT TO ALL THERAPIES, INCLUD… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | TAMPA, FL-15 | 2024 | $3,355,999 |
ASST_NON_R01CA266803_075 AN IONIZING RADIATION ACOUSTICS IMAGING (IRAI) APPROACH FOR GUIDED FLASH RADIOTHERAPY - SUMMARY AN EMERGING RADIOTHERAPY (RT) MODALITY THAT UTILIZES ULTRA-HIGH DOSE RATE, KNOWN AS… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | TAMPA, FL-15 | 2024 | $3,262,628 |
ASST_NON_R01CA256193_075 CHARACTERIZATION AND TARGETING OF THE EPIGENETIC STATE UNDERLYING UVEAL MELANOMA LIVER METASTASIS - UVEAL MELANOMA (UM) IS A HIGHLY AGGRESSIVE AND FREQUENTLY FATAL CANCER OF THE E… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | TAMPA, FL-15 | 2024 | $3,231,041 |
ASST_NON_U01CA232382_075 ECO-EVOLUTIONARY DYNAMICS OF NSCLC TO IMMUNOTHERAPY: RESPONSE AND RESISTANCE - ABSTRACT WORLDWIDE, NON-SMALL CELL LUNG CANCER (NSCLC) IS THE MOST COMMON AND AMONG THE MOST LETHAL… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | TAMPA, FL-15 | 2024 | $3,206,301 |
ASST_NON_R35GM133482_075 ILLUMINATING NOTCH RECEPTOR-LIGAND SELECTIVITY THROUGH STRUCTURE-GUIDED PROTEIN ENGINEERING - PROJECT SUMMARY OVERALL VISION OF THE RESEARCH PROGRAM. MY LAB USES STRUCTURE-GUIDED… | Department of Health and Human Services National Institutes of Health | 93.859 BIOMEDICAL RESEARCH AND RESEARCH TRAINING | FL-90 | 2025 | $3,183,836 |
ASST_NON_R01CA258089_075 ECO-EVOLUTIONARY DRIVERS OF CLONAL DYNAMICS DURING UV-INDUCED SKIN CARCINOGENESIS (PQ3) - ABSTRACT CANCERS HAVE READILY-DEFINED CHARACTERISTICS OFTEN REFERRED TO AS “HALLMARKS”. N… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | TAMPA, FL-15 | 2024 | $3,142,500 |
ASST_NON_R01DK125367_075 IMPROVING WEIGHT LOSS OUTCOMES OF BLACK WOMEN USING A CULTURALLY RELEVANT, STRESS MANAGEMENT ENHANCEMENT BEHAVIORAL WEIGHT LOSS INTERVENTION - BLACK FEMALES HAVE THE HIGHEST PREVA… | Department of Health and Human Services National Institutes of Health | 93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | TAMPA, FL-15 | 2024 | $3,126,095 |
ASST_NON_R01CA212097_075 CELL FREE NUCLEIC ACID-BASED BIOMARKERS IN ADVANCED PROSTATE CANCER - PROJECT SUMMARY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IS TREATED WITH ANDROGEN DEPRIVATION THERAPY AND… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | FL-90 | 2024 | $3,069,881 |
ASST_NON_R01CA243552_075 RANDOMIZED TRIAL OF AUTOMATED VIDEO-ASSISTED SMOKING TREATMENT FOR PEOPLE LIVING WITH HIV - SUMMARY MODERN ANTIRETROVIRAL THERAPY HAS BROUGHT ABOUT SIGNIFICANTLY INCREASED LIFE EX… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | FL-90 | 2024 | $3,053,148 |
ASST_NON_R01DA055298_075 AUGMENTED REALITY AS AN ADJUNCT TO QUITLINE COUNSELING FOR SMOKING CESSATION - PROJECT SUMMARY/ABSTRACT CIGARETTE SMOKING REMAINS THE LEADING PREVENTABLE CAUSE OF MORBIDITY AND MO… | Department of Health and Human Services National Institutes of Health | 93.279 DRUG USE AND ADDICTION RESEARCH PROGRAMS | TAMPA, FL-15 | 2024 | $3,040,122 |
ASST_NON_R01CA235032_075 PHASE II CLINICAL TRIAL OF GTC IN MEN ON ACTIVE SURVEILLANCE - ABSTRACT: THE ERA OF SCREENING FOR PROSTATE CANCER (PCA) USING SERUM PROSTATE SPECIFIC ANTIGEN (PSA) HAS LED TO AN I… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | TAMPA, FL-15 | 2024 | $3,012,672 |
ASST_NON_CE152143_075 COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING - CONSTRUCTION - H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC (“MOFFITT”) IS A NATIONAL LEADER IN INNOVATIV… | Department of Health and Human Services Health Resources and Services Administration | 93.493 CONGRESSIONAL DIRECTIVES | TAMPA, FL-90 | 2024 | $3,000,000 |
ASST_NON_R01CA302303_075 TRENDS AND OUTCOMES OF LUNG CANCER SCREENING AMONG PEOPLE WITH AND WITHOUT HIV IN THE US - IN THE UNITED STATES (US), LUNG CANCER IS THE LEADING CAUSE OF CANCER-RELATED MORTALITY… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | FL-90 | 2025 | $2,991,283 |
ASST_NON_U01CA261598_075 ENDING TOBACCO USE THROUGH INTERACTIVE TAILORED MESSAGING FOR CAMBODIAN PEOPLE LIVING WITH HIV/AIDS (ENDIT) - ALTHOUGH THE PREVALENCE OF TOBACCO USE HAS DECLINED IN DEVELOPED NATI… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | TAMPA, FL-15 | 2024 | $2,979,791 |
ASST_NON_R01CA214647_075 RANDOMIZED PLACEBO CONTROLLED TRIAL OF BUPROPION FOR CANCER RELATED FATIGUE - PROJECT SUMMARY FATIGUE IS ONE OF THE MOST PREVALENT AND DISTRESSING SYMPTOMS EXPERIENCED BY CANCER P… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | FL-90 | 2024 | $2,967,093 |
ASST_NON_R01CA231952_075 PARTNERING WITH A STATE FOOD BANK TO PROVIDE TOBACCO TREATMENT TO UNDERSERVED SMOKERS - SUMMARY EFFICIENTLY CONNECTING UNDERSERVED SMOKERS WITH LIMITED RESOURCES TO EFFICACIOUS TO… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | FL-90 | 2024 | $2,912,626 |
ASST_NON_R01CA272601_075 MODELING THE ROLE AND REGULATION OF REACTIVE STROMA IN BREAST DUCTAL CARCINOMA MICROINVASIONS - DUCTAL CARCINOMA IN SITU (DCIS) OF THE BREAST IS A HETEROGENEOUS GROUP OF NEOPLASTI… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | FL-90 | 2024 | $2,877,838 |
ASST_NON_R01CA255265_075 EFFICACY OF A MINDFULNESS-BASED STRESS MANAGEMENT PROGRAM FOR ALLOGENEIC HCT CAREGIVERS - PROJECT SUMMARY/ABSTRACT CARING FOR AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HCT… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | TAMPA, FL-15 | 2024 | $2,839,105 |
ASST_NON_R37CA230042_075 INVESTIGATION OF NRF2-DEPENDENT METABOLIC LIABILITIES - METABOLIC REPROGRAMMING OCCURS DURING TUMORIGENESIS AND HOLDS PROMISE FOR CANCER THERAPY. HOWEVER, THE UNDERLYING MECHANISM… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | FL-90 | 2024 | $2,829,529 |
ASST_NON_R01CA199143_075 EXPANDING THE REACH OF A VALIDATED SMOKING-CESSATION INTERVENTION: A SPANISH-LANGUAGE RCT - DESCRIPTION (PROVIDED BY APPLICANT): TOBACCO SMOKING IS THE LEADING PREVENTABLE CA… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | TAMPA, FL-15 | 2024 | $2,777,175 |
ASST_NON_R01CA244328_075 NEUROCOGNITIVE AND PATIENT-REPORTED OUTCOMES AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: A CONTROLLED COMPARISON - PROJECT SUMMARY THERE IS WIDESPREAD EXCITEMENT ABOUT CHIMERI… | Department of Health and Human Services National Institutes of Health | 93.393 CANCER CAUSE AND PREVENTION RESEARCH | TAMPA, FL-15 | 2024 | $2,766,745 |
ASST_NON_R01CA241713_075 NEW THERAPEUTIC VULNERABILITIES FOR AGGRESSIVE B-CELL LYMPHOMA - PROJECT SUMMARY DOUBLE-HIT LYMPHOMA (DHL) AND DOUBLE-EXPRESSING LYMPHOMA (DEL) ARE AGGRESSIVE SUBTYPES OF DIFFUSE… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | FL-90 | 2024 | $2,723,719 |
ASST_NON_R37CA264518_075 DISRUPTING THE PROSTATE TUMOR MICROENVIRONMENT IN AFRICAN AMERICAN MEN TO PROMOTE RESPONSE TO IMMUNO-MODULATORY THERAPY - MEN WITH AFRICAN ANCESTRY (AAM) ARE KNOWN TO PRESENT WITH… | Department of Health and Human Services National Institutes of Health | 93.396 CANCER BIOLOGY RESEARCH | TAMPA, FL-15 | 2024 | $2,642,372 |
ASST_NON_T32CA090314_075 BEHAVIORAL ONCOLOGY EDUCATION & CAREER DEVELOPMENT - CONSISTENT WITH RECENT NCI PRIORITIES, THERE IS AN URGENT NEED FOR NEW INVESTIGATORS TO DEVELOP SKILLS TO BROADEN THE TRANSLAT… | Department of Health and Human Services National Institutes of Health | 93.398 CANCER RESEARCH MANPOWER | FL-90 | 2024 | $2,578,778 |
Top 50 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Federal Programs (CFDA)
View All→12345678910
93.397 — CANCER CENTERS SUPPORT GRANTS$94.3M
93.396 — CANCER BIOLOGY RESEARCH$82.6M
12.420 — MILITARY MEDICAL RESEARCH AND DEVELOPMENT$69.9M
93.395 — CANCER TREATMENT RESEARCH$69.7M
93.393 — CANCER CAUSE AND PREVENTION RESEARCH$58.9M
93.394 — CANCER DETECTION AND DIAGNOSIS RESEARCH$25.4M
93.398 — CANCER RESEARCH MANPOWER$10.3M
93.859 — BIOMEDICAL RESEARCH AND RESEARCH TRAINING$9.9M
93.121 — ORAL DISEASES AND DISORDERS RESEARCH$8.4M
93.493 — CONGRESSIONAL DIRECTIVES$6.0M
Source: USAspending.gov · All Recipients · Utah